Business Wire

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

Share

Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II EffisayilTM 1 trial, which showed spesolimab, a first-in-class investigational treatment, significantly improved signs and symptoms of generalized pustular psoriasis (GPP) in patients experiencing a flare.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005031/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GPP is a rare, life-threatening neutrophilic skin disease, which is distinct from plaque psoriasis. It is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).2,3,4 There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life5 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure and sepsis and even death.6

In the 12-week trial, 53 patients experiencing a GPP flare were treated with a single intravenous dose of spesolimab or placebo. Most patients at the outset of the trial had a high or very high density of pustules and impaired quality of life. Results after one week demonstrated that:

  • 54% of patients treated with spesolimab showed no visible pustules compared to 6% of those treated with placebo;
  • 43% of patients treated with spesolimab showed clear/almost clear skin compared to 11% of those in the placebo group.1

Pustular and skin clearance continued for the duration of the study. This clearance was accompanied by clinically significant improvements in quality of life and symptoms such as pain and fatigue, compared to placebo.1

Over the 12-week duration of the study, non-serious infections rates were higher in the spesolimab group compared with placebo, with no pattern regarding pathogen and affected organs. Two patients reported to have drug reactions with eosinophilia and systemic symptoms.

“With no approved treatments in the U.S. or E.U. for GPP flares, there is a significant unmet need for people with this distressing and painful skin condition, that often requires emergency care,” said Mark Lebwohl, MD, lead investigator and publication author, and Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai, Kimberly and Eric J. Waldman Department of Dermatology, New York. “These clinical trial results show that spesolimab has the potential to completely clear the skin of the signs and symptoms of a GPP flare after only one week, with sustained effect observed for up to 12 weeks.”

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for the treatment of GPP, and Breakthrough Therapy Designation for spesolimab for the treatment of GPP flares. This designation is for therapies treating serious or life-threatening conditions where early clinical evidence suggests a substantial improvement compared to existing treatments. The Chinese Regulatory Authority Centre for Drug Evaluation (CDE) also recently granted Breakthrough Therapy Designation for spesolimab for the treatment of GPP flares.

“At Boehringer Ingelheim, we are committed to finding transformative therapies to help advance treatment for people who urgently need them,” said Dr Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, Boehringer Ingelheim. “The findings indicate that spesolimab may have a significant and positive impact on patients experiencing a GPP flare.”

The clinical program for spesolimab includes two other trials that are currently underway. First, the Effisayil-2 trial is designed to investigate spesolimab as a maintenance treatment to prevent the occurrence of GPP flares. The Effisayil-ON trial is an open label five-year extension study to investigate the longer term efficacy and safety of spesolimab in patents with GPP.7,8

Please click on the following link for ‘Notes to Editors’: https://www.boehringer-ingelheim.com/human-health/skin-diseases/gpp/spesolimab-phase-ii-data

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR

Dr Julia Fass
Phone: +49 (6132) 77 95614
Fax: +49 (6132) 77 6601
Email: press@boehringer-ingelheim.com

Additional information
www.boehringer-ingelheim.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dr. Philip Krause to Provide Strategic Advice to Adjuvance25.1.2022 15:35:00 CET | Press release

Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced that Philip Krause, MD, will take on a strategic consulting role with the organization as it advances its vaccine development portfolio. Dr. Krause recently served as the Deputy Director, Office of Vaccines Research and Review of the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research. “The deep scientific, regulatory and vaccine development experience that Phil brings to Adjuvance will be instrumental in efficiently developing our shingles vaccine candidate and our pipeline anchored on the next-generation saponin adjuvant TQL-1055,” noted Dr. Tyler Martin, Adjuvance CEO, President and Chairman. “I am thrilled to enhance the company’s expertise with such a well-respected scientist.” Dr. Krause previously had a 30-year career in the FDA where he made majo

Andersen Global Adds Member Firms in Croatia25.1.2022 15:30:00 CET | Press release

Andersen Global continues to cultivate a strong European presence as Croatian tax and advisory firm Andersen BD d.o.o. (formerly BD Savjetovanje d.o.o.) becomes the organization’s newest member firm to adopt the Andersen brand. Andersen Global also welcomes member firm KALLAY & PARTNERS, a Zagreb-based law firm and collaborating firm since 2019. Together, the member firms will provide complementary tax and legal solutions, demonstrating the unified and seamless approach of the global organization. “As tax and legal legislation globally becomes more complex, we aim to continue providing best-in-class service and help our clients navigate the various aspects of their business operations,” said Branka Topolovec new Managing Partner of Andersen in Croatia. “The adoption of the Andersen brand is a milestone for our firm’s growth and development and gives us a competitive advantage in the market by allowing us to provide our clients with a full suite of capabilities in Croatia as well as glo

UVD Robots Joins Ecolab’s Global Infection Prevention Offerings to Fight Hospital Acquired Infections25.1.2022 15:02:00 CET | Press release

As new coronavirus variants spread, the growth in demand for infection prevention solutions using UV-C light is projected to reach $18.94 billion by 2030, witnessing an annual growth rate of 59.7% from 2021 to 2030. Further fueling the demand is the rise in hospital acquired infections (HAIs) globally causing more fatalities due to the increase in antibiotic resistance from even simple infections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005148/en/ Disinfecting hospitals with UV-C lights is not a new concept, however, existing solutions including UV ceiling lights, stationary cleaning robots, and air purifiers may not reach shadowed or remote areas as well as the mobile platform offered by the autonomous UVD Robots. (Photo: Business Wire) Autonomous UV-C disinfection robots have emerged as a solution to supplement standard cleaning and disinfection practices to address HAIs and heightened hygiene requirements due

Alvaria Adds Real Time Intelligent AI Capability to Optimize Enterprise Contact Center Employees25.1.2022 15:00:00 CET | Press release

Alvaria, the world leader in enterprise-scale customer experience and workforce engagement management, announced the introduction of Alvaria Real Time Optimizer, a new cloud application of the Alvaria Workforce Engagement Management Suite that enhances the contact center agent experience. By functioning as a real-time virtual agent assistant, Alvaria Real Time Optimizer call center application completes activities, which positively impact key performance metrics, such as: Automatically monitors agent idle time and delivers training, coaching and off-phone tasks when service levels can best accommodate. – Streamlines communications Boost agent morale with automated delivery of surprise breaks, wellness breaks etc. – Increase agent satisfaction and engagement Automatically find the right time to connect agents with supervisors to ensure individual coaching is completed. – Protecting Service Level Consistently prompts agents with a helping hand when they go beyond thresholds for talk, hol

CSC Research Finds Third Parties Continue to Lay Groundwork for Malicious Activity Among Thousands of COVID-Related Domains25.1.2022 15:00:00 CET | Press release

CSC, a world leader in business, legal, tax, and domain security, today announced key findings from its new report, which found that nearly 500,000 web domains were registered since January 2020 containing key COVID-related terms. Many of these web domains can pose threats to brands and consumers due to their registration patterns and behaviors. This research is part of CSC’s latest report, “Two Year Analysis: The Impact of COVID-19 on Internet Security and Safety." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005112/en/ (Graphic: Business Wire) The report’s findings are gathered using CSC’s newly launched DomainSecSM platform, which makes the connections between newly registered, dropped, and existing domain names, online brands, and fraud (phishing). DomainSec is the first of its kind to deliver a holistic approach for securing and defending brands’ domain portfolio ecosystems. It uses proprietary technology combin

Bird Scales European Operations with Recent Permit Wins in France, Italy and the Netherlands25.1.2022 15:00:00 CET | Press release

Bird Global, Inc. (NYSE:BRDS), a leader in environmentally friendly electric transportation, today announced expansion of its micro-electric vehicle sharing service in the Dutch city of Amersfoort. The launch marks the debut of the company’s shared e-assist bikes in the Netherlands and builds on Bird’s recent e-assist bike permit awards and launches in Bordeaux, France and Rome, Italy. As demand for micro-electric vehicles continues throughout Europe, Bird is scaling the availability of its bike share service which complements its original e-scooter sharing offering. Following the launch in the Netherlands, the company plans to apply its operations permit to deliver a bike sharing service in Sesto Fiorentino, a town in the metropolitan area of Florence, Italy. The impending launch in Italy’s eighth-largest city will further Bird’s position as a leading micromobility provider in the country. Bird is now operational in over 350 cities globally including in more than 150 cities throughout

Merkle Unveils 2022 Imperatives to Address Customer Experience in a New Age25.1.2022 15:00:00 CET | Press release

Merkle (www.merkleinc.com), a leading technology-enabled, data-driven customer experience management (CXM) company, has unveiled its 2022 Customer Experience Imperatives. The executive guide is designed to help brands identify the key strategic considerations that will shape the year ahead and provide business leaders with actionable insights to create competitive advantage through marketing. This year, the Imperatives explore three themes, including data, measurement, and commerce’s impact on loyalty, and discuss how brands can approach each of these to stay ahead of the curve within their industries. “At Merkle, we are dedicated to helping brand leaders understand the role customer experience plays in driving their business forward. In the coming year, establishing deeper and more rewarding relationships with its customers will be a necessity for any business to achieve its goals,” said Michael Komasinski, global chief executive officer at Merkle/CXM. “The 2022 Customer Experience Im

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom